MX2019010659A - Inhibidores de beta secretasa. - Google Patents

Inhibidores de beta secretasa.

Info

Publication number
MX2019010659A
MX2019010659A MX2019010659A MX2019010659A MX2019010659A MX 2019010659 A MX2019010659 A MX 2019010659A MX 2019010659 A MX2019010659 A MX 2019010659A MX 2019010659 A MX2019010659 A MX 2019010659A MX 2019010659 A MX2019010659 A MX 2019010659A
Authority
MX
Mexico
Prior art keywords
beta
dementia
compounds
compositions
secretase
Prior art date
Application number
MX2019010659A
Other languages
English (en)
Inventor
Jesús Alcázar-Vaca Manuel
Jacobus Johannes Antonius Buijnsters Peter
Oehlrich Daniel
Jacobus Maria Gijsen Henricus
Franciscus Anna Van Brandt Sven
Marleen Vos Ann
Shawn Watts Karl
Pangala BHAT Sathesh
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2018/055402 external-priority patent/WO2018162444A1/en
Publication of MX2019010659A publication Critical patent/MX2019010659A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La presente invencion se refiere a inhibidores tricíclicos de beta?secretasa que tienen la estructura mostrada en las formulas (I) y (II) (ver formulas) (I) y (II) y los tautomeros y las formas estereoisomericas de los mismos, en los que los radicales son tal como se definen en la memoria descriptiva; la invencion se dirige tambien a composiciones farmaceuticas que comprenden este tipo de compuestos, a procedimientos para preparar compuestos y composiciones de este tipo y al uso de compuestos y composiciones de este tipo para la prevención y el tratamiento de trastornos en los que esta implicada beta-secretasa tales como la enfermedad de Alzheimer (EA), defecto cognitivo leve, senilidad, demencia, demencia con cuerpos de Lewy, síndrome de Down, demencia asociada a apoplejía, demencia asociada con la enfermedad de Parkinson, demencia asociada con beta-amiloide, degeneración macular relacionada con la edad, diabetes tipo 2 y otros trastornos metabólicos.
MX2019010659A 2017-03-07 2018-03-06 Inhibidores de beta secretasa. MX2019010659A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762467998P 2017-03-07 2017-03-07
EP17189756 2017-09-07
PCT/EP2018/055402 WO2018162444A1 (en) 2017-03-07 2018-03-06 Inhibitors of beta secretase

Publications (1)

Publication Number Publication Date
MX2019010659A true MX2019010659A (es) 2019-10-21

Family

ID=61616994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010659A MX2019010659A (es) 2017-03-07 2018-03-06 Inhibidores de beta secretasa.

Country Status (9)

Country Link
US (1) US20210284659A1 (es)
EP (1) EP3592751A1 (es)
JP (1) JP2020509074A (es)
KR (1) KR20190126828A (es)
CN (1) CN110382507A (es)
AU (1) AU2018229722A1 (es)
CA (1) CA3051373A1 (es)
MA (1) MA47730A (es)
MX (1) MX2019010659A (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
US20120245155A1 (en) * 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group

Also Published As

Publication number Publication date
CN110382507A (zh) 2019-10-25
JP2020509074A (ja) 2020-03-26
CA3051373A1 (en) 2018-09-13
KR20190126828A (ko) 2019-11-12
MA47730A (fr) 2020-01-15
EP3592751A1 (en) 2020-01-15
AU2018229722A1 (en) 2019-08-08
US20210284659A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2017008083A (es) Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.
EA201390419A1 (ru) ПРОИЗВОДНЫЕ 4,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-6-ИЛАМИНА, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (ВАСЕ)
EA201291435A1 (ru) Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace)
UA109800C2 (xx) ПОХІДНІ 6,7-ДИГІДРОПІРАЗОЛО$1,5-a]ПІРАЗИН-4-ІЛАМІНУ, КОРИСНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
EA201291366A1 (ru) Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace)
EA201390932A1 (ru) ПРОИЗВОДНЫЕ 5,6-ДИГИДРОИМИДАЗО[1,2-а]ПИРАЗИН-8-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (ВАСЕ)
MY163346A (en) 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (base)
BR112012033291A2 (pt) derivados de 3-amino-5,6-di-hidro-1h-piranzin-2-ona úteis para o tratamento de doença de alzheimer e outras formas de demência
MX357383B (es) Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina.
MY165209A (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
MX2015017151A (es) Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5 a]pirazin-3(2h)-ona como inhibidores de beta-secretasa (bace).
MX2015017153A (es) Derivados de 4-a mino-6-fenil-5,6-dihidroimidazo[1,5 a]pirazina como inhibidores de beta-secretasa (bace).
EA201592307A1 (ru) Производные 4-амино-6-фенил-6,7-дигидро[1,2,3]триазоло[1,5-a]пиразина в качестве ингибиторов бета-секретазы (bace)
MX2018003565A (es) Derivados de 2,3,4,5-tetrahidropiridin-6-amina.
MX2019010659A (es) Inhibidores de beta secretasa.
MX2019010649A (es) Inhibidores de beta secretasa.
MX2019010653A (es) Inhibidores de beta secretasa.
EA201992108A1 (ru) Ингибиторы бета-секретазы
EA201992076A1 (ru) Ингибиторы бета-секретазы
EA201992055A1 (ru) Ингибиторы бета-секретазы
MX2019002125A (es) Derivados de hidroxinorketamina para el tratamiento de trastornos.
MX2019005247A (es) Compuestos 4,4a,5,7-tetrahidro-3h-furo[3,4-b]piridinilicos.